Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy

Дата публикации: 18-06-2026 00:00:00

This systematic review and meta-analysis estimates the frequency of reported second primary malignant neoplasms after T-cell–engaging bispecific antibody therapy and evaluates whether study-level characteristics and reporting definitions influence observed estimates.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer	0	7	25-06-2026
2	Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors	0	7	25-06-2026
3	Three-Body Problem at Digital Frontiers	0	5	25-06-2026
4	Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer	0	5	18-06-2026
5	Error in Open Access License	0	5	18-06-2026
6	Less Can Be More by Circulating Tumor DNA Use in ERBB2 -Positive Breast Cancer	0	7	25-06-2026
7	Survival in the SONIA Trial	0	8	18-06-2026
8	Survival in the SONIA Trial	0	7	18-06-2026
9	Team finds way to reverse ovarian cancer’s chemo resistance	5	8	25-06-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 7. Источник: jamanetwork.com.